Biogen subpoenaed by federal government over MS drug prices
Biogen disclosed Thursday that it received a subpoena late last year from federal investigators related to the price of its top multiple sclerosis drugs, including blockbuster treatment Tecfidera.
Cambridge-based Biogen (Nasdaq: BIIB) said in its annual federal filing that it had received a subpoena on Dec. 5 seeking information regarding "government price reporting, rebate payments and Biogen's co-pay assistance programs" for MS drugs Tecfidera, Avonex, Tysabri and Plegridy. The company sa id it… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - February 2, 2017 Category: Biotechnology Authors: Max Stendahl Source Type: news
Biogen subpoenaed by federal government over MS drug prices
Biogen disclosed Thursday that it received a subpoena late last year from federal investigators related to the price of its top multiple sclerosis drugs, including blockbuster treatment Tecfidera.
Cambridge-based Biogen (Nasdaq: BIIB) said in its annual federal filing that it had received a subpoena on Dec. 5 seeking information regarding "government price reporting, rebate payments and Biogen's co-pay assistance programs" for MS drugs Tecfidera, Avonex, Tysabri and Plegridy. The company sa id it… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - February 2, 2017 Category: American Health Authors: Max Stendahl Source Type: news
Elevated Natalizumab Levels in MS May Not Be Linked With PML Risk Elevated Natalizumab Levels in MS May Not Be Linked With PML Risk
In multiple sclerosis (MS) patients treated with natalizumab, the risk of developing progressive multifocal leukoencephalopathy (PML) does not appear to be associated with high blood levels of the drug, preliminary research from the Netherlands suggests.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - January 3, 2017 Category: Consumer Health News Tags: Neurology & Neurosurgery News Source Type: news
Perrigo to review options for Multiple Sclerosis drug Tysabri
(Reuters) - Perrigo Co Plc reported a higher-than-expected adjusted quarterly profit and said it would review strategic options for royalty rights from sales of multiple sclerosis drug Tysabri. (Source: Reuters: Health)
Source: Reuters: Health - November 10, 2016 Category: Consumer Health News Tags: healthNews Source Type: news
Alemtuzumab Comparison Data Show Some Surprises Alemtuzumab Comparison Data Show Some Surprises
New observational propensity-matched data on head-to-head comparisons of alemtuzumab with beta-interferon, fingolimod, and natalizumab show some unexpected findings.Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - September 29, 2016 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news
MRI May Help Differentiate Asymptomatic PML From New MS Lesions MRI May Help Differentiate Asymptomatic PML From New MS Lesions
MRI criteria can be used to differentiate asymptomatic progressive multifocal leukoencephalopathy (PML) from new multiple sclerosis (MS) lesions during natalizumab pharmacovigilance, researchers from the Netherlands report.Reuters Health Information (Source: Medscape Radiology Headlines)
Source: Medscape Radiology Headlines - September 21, 2016 Category: Radiology Tags: Neurology & Neurosurgery News Source Type: news
Registry Data: Lemtrada More Effective than Competing MS Tx
(MedPage Today) -- Better than fingolimod or interferon; comparable to natalizumab (Source: MedPage Today Meeting Coverage)
Source: MedPage Today Meeting Coverage - September 17, 2016 Category: Journals (General) Source Type: news
ECTRIMS: Rituximab Beats MS Drugs in Swedish Registry Study (CME/CE)
(MedPage Today) -- Finds survival advantage for rituximab over fingolimod and natalizumab (Source: MedPage Today State Required CME)
Source: MedPage Today State Required CME - September 16, 2016 Category: Consumer Health News Source Type: news
Extended Interval Dosing of Natalizumab in Multiple Sclerosis Extended Interval Dosing of Natalizumab in Multiple Sclerosis
Could risk of PML with natalizumab be reduced in MS patients, without compromising efficacy, by extending the interval between doses?Journal of Neurology, Neurosurgery, and Psychiatry (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 12, 2016 Category: Consumer Health News Tags: Neurology & Neurosurgery Journal Article Source Type: news
Tysabri (Natalizumab) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - June 1, 2016 Category: Drugs & Pharmacology Source Type: news
Relapses Rebound in Patients With MS Stopping FingolimodRelapses Rebound in Patients With MS Stopping Fingolimod
As seen with natalizumab, a new study shows patients may experience rebound in relapses after stopping fingolimod. Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - May 12, 2016 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news
Natalizumab Misses Endpoint in Secondary Progressive MSNatalizumab Misses Endpoint in Secondary Progressive MS
In the ASCEND trial, treatment did not delay disease progression, the primary endpoint, although there was a benefit on upper-extremity function. Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - April 26, 2016 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news
Rituximab outperforms fingolimod after natalizumab switch
Rituximab is more effective and better tolerated than fingolimod for patients with multiple sclerosis needing to switch from natalizumab due to JC-virus antibody positivity, research suggests. (Source: MedWire News)
Source: MedWire News - April 26, 2016 Category: Consumer Health News Tags: Multiple sclerosis Source Type: news
Tysabri No Help in SPMS
(MedPage Today) -- Drug didnt reduce disability progression but may benefit upper limb function (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - April 22, 2016 Category: Primary Care Source Type: news
Rituximab is superior to fingolimod for certain patients with multiple sclerosis
A new study indicates that rituximab is more effective than fingolimod for preventing relapses in patients with highly active multiple sclerosis switching from treatment with natalizumab. The study included patients infected with JC virus, which is present in approximately 50% of the general population. While the virus generally causes no problems under normal circumstances, it can cause progressive multifocal leukoencephalopathy (PML), a serious demyelinating disease of the brain, in patients with immune deficiencies due to disease or immunosuppressant drugs. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - April 21, 2016 Category: Science Source Type: news
